KalVista Pharmaceuticals, Inc.KALVNASDAQ
Loading
Net Income Growth AcceleratingAccelerating
Percentile Rank82
3Y CAGR+73.1%
5Y CAGR+37.5%
Year-over-Year Change
Year-over-year net income growth rate
3Y CAGR
+73.1%/yr
vs -35.2%/yr prior
5Y CAGR
+37.5%/yr
Recent acceleration
Acceleration
+108.2pp
Accelerating
Percentile
P82
Within normal range
vs 5Y Ago
4.9x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 17.66% |
| Q3 2025 | -15.07% |
| Q2 2025 | -7.66% |
| Q1 2025 | -14.77% |
| Q4 2024 | -4.51% |
| Q3 2024 | 9.42% |
| Q2 2024 | -53.81% |
| Q1 2024 | -4.98% |
| Q4 2023 | -9.22% |
| Q3 2023 | 3.76% |
| Q2 2023 | -23.48% |
| Q1 2023 | 4.29% |
| Q4 2022 | 3.41% |
| Q3 2022 | 4.44% |
| Q2 2022 | -7.33% |
| Q1 2022 | -14.34% |
| Q4 2021 | -21.98% |
| Q3 2021 | -7.71% |
| Q2 2021 | -48.85% |
| Q1 2021 | 3.63% |
| Q4 2020 | 3.59% |
| Q3 2020 | -64.25% |
| Q2 2020 | 29.14% |
| Q1 2020 | -57.39% |
| Q4 2019 | 19.56% |
| Q3 2019 | 13.93% |
| Q2 2019 | -115.52% |
| Q1 2019 | -19.73% |
| Q4 2018 | 34.31% |
| Q3 2018 | -665.60% |
| Q2 2018 | 87.45% |
| Q1 2018 | -4.97% |
| Q4 2017 | -1.18% |
| Q3 2017 | -17.28% |
| Q2 2017 | 45.03% |
| Q1 2017 | 0.00% |
| Q3 2016 | 100.00% |
| Q2 2016 | 64.20% |
| Q1 2016 | -16.75% |
| Q4 2015 | -13.38% |